Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Abstract: Provided herein are drug implants comprising Darolutamide for the treatment of disease in a subject. In some cases, the drug implant may comprise a polymer matrix and Darolutamide disposed therein. Additionally provided are methods for manufacturing the drug implants and methods of treating diseases with the implants. In some cases, the drug implant may be used for the treatment of a proliferative disease of the prostate.

Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

Abstract: The present disclosure related to methods of treating pruritus in a subject by topically administering detomidine, or a pharmaceutically acceptable salt thereof, to the subject.

Abstract: The present disclosure provides a photocurable hydrogel loaded with VH298-modified exosome and a method of preparation and use thereof, belonging to the technical field of medical materials. In the present disclosure, an engineered exosome (VH-EVs) is prepared by combining an exosome with VH298, a hypoxia-inducible factor 1 alpha (HIF-1?) stabilizer; and a solid auxiliary material is loaded by a GelMAhydrogel. The material is not only conducive to sustained release of the engineered exosome, but improves angiogenesis and accelerate wound healing, showing a relatively high value for use.

Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

Abstract: An oral preparation, specifically including a JAK inhibitor and pharmaceutical excipients is provided, wherein the JAK inhibitor includes a compound of formula (I), an isomer thereof, pharmaceutically acceptable salts thereof, or their crystal form. The oral preparation of the present application has the characteristic of rapid dissolution. The oral preparation process of the present application is simple and suitable for large-scale industrial production.

Abstract: Methods of treating a disease caused by a positive strand RNA virus. The methods include administering to a subject in need thereof an effective amount of a compound of Formula I.

Abstract: The present invention relates to a pharmaceutical use of a PPARS inhibitor in combination with an immunotherapeutic drug for preparing an anti-tumor drug, wherein the immunotherapeutic drug is an immune agonist or an immune checkpoint inhibitor, the tumor is preferably melanoma, mammary cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, esophageal cancer, colorectal cancer, colonic cancer, lymphoma, brain tumor, sarcoma, cervical cancer, prostate cancer, bladder cancer, osteosarcoma, head and neck cancers, renal cell carcinoma, or stomach cancer. The medicine of the present invention exhibits significant anti-cancer effect, strong targeting ability which has little side effect.

Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.

Abstract: The present disclosure relates to methods and compositions for treating or preventing a beta-coronavirus infection, or for inhibiting symptoms of a disease caused by a beta coronavirus infection in a subject, including SARS-CoV-2 and COVID-19. In various embodiments, the composition and methods involve a combination of a non-steroidal anti-inflammatory drug (NSAID) and ketotifen. In exemplary embodiments, naproxen and/or indomethacin are combined with ketotifen for therapy in a single unit dose or separate compositions, and the combination is surprisingly and unexpectedly effective to reduce SARS-CoV-2 viral load and treat COVID-19.

Abstract: The subject invention pertains to compositions comprising atropine at a concentration of greater than 0.025% to about 0.05% and methods of administering said compositions to a subject to inhibit or delay the onset of myopia in pre-myopic patients.

Abstract: The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: The subject invention provides pharmaceutical compositions comprising combinations of probenecid or a pharmaceutically acceptable salt thereof, and one or more carboxylic acid aldose reductase inhibitors (ARIs) or pharmaceutically acceptable salts thereof. The subject invention also provides methods of using such combinations to treat mammals, including humans, suffering from diabetic complications such as, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cataracts, diabetic cardiovascular complications, including cardiomyopathy, myocardial infarction, heart failure and atherosclerosis and non-diabetic cardiovascular complications, including myocardial infarction, coronary artery disease, atherosclerotic cardiovascular diseases and heart failure.

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

Abstract: The present invention relates to useful methods of treating Acute Myeloid Leukemia (AML) in a human. in the presence of gene mutations.

Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.

Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.

Abstract: A composition for improving mental energy. In one embodiment, the composition comprises Caffeine, L-Theanine, L-Ornithine, B-complex vitamins—Thiamine (B1), Riboflavin (B2), Niacinamide (B3), Pantothenic Acid (B5), Pyridoxal 5?-phosphate (B6), Folate (B9), and Methylcobalamin (B12). In certain embodiments, the composition further comprises Celastrus paniculatus Seed Extract, American Ginseng (Panax quinquefolius) Root Extract, or a combination thereof. In other embodiments, the composition further includes Ginger Root Extract, Ginkgo biloba Leaf Extract, or a combination thereof. In certain embodiments, the composition is incorporated into pills. The composition boosts the sense of mental energy during the day, manifesting as increased alertness, attention, focus, mood, and motivation, by promoting brain energy production and a wide range of brain and nervous system functions that support mental energy.

Abstract: The disclosed technology relates generally to compositions, methods, and system for utilizing paraxanthine alone and in combination for use in enhancing immune function and/or inhibiting inflammation through administration of a paraxanthine-containing composition to a subject. More particularly, the disclosure relates to paraxanthine and other compounds, whether produced synthetically or derived from natural sources, and use of these compounds to provide physiological benefits, which may vary according to paraxanthine concentration and the presence of synergists and antagonists.

Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.

Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2?,4?-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for inhibiting, reducing, or treating chronic kidney disease or/and renal fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with herpes simplex virus. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, myoclonic, absence and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: A topical cannabinoid composition is disclosed, including a cannabinoid and a numbing agent. A method for making the topical cannabinoid composition is disclosed, including melting and combining butters and oils, then heating and adding waxes, then adding a numbing agent, and then adding at least one cannabinoid and, optionally, at least one terpene, to form the topical cannabinoid composition. A method for treating a skin condition is disclosed, including applying the topical cannabinoid composition to skin tissue having the skin condition. An anti-inflammatory cannabinoid composition is disclosed, including at least two but less than five species selected from the group consisting of cannabidiol, cannabidiolic acid, caryophyllene, pinene, and humulene. A method for reducing an inflammatory response associated with a viral infection is disclosed, including administering the anti-inflammatory cannabinoid composition to an individual experiencing the inflammatory response associated with the viral infection.

Abstract: The use of cannabis and/or its parts (e.g., cannabinoids, CBD, THC, cannabidiol, hemp) to treat or reduce the effects caused by exposure to glyphosate, glyphosate derivatives, glyphosate disorders, and/or glyphosate toxicity in the human body and/or other animals. Also, methods of administering, to a patient (either a human or an animal), a product derived from the cannabis plant to treat exposure to glyphosate, glyphosate toxicity and/or glyphosate disorder.

Abstract: A method of producing pure cannabidiol (CBD) isolate crystals including the steps of extracting the CBD compound from a cannabis plant; winterizing to remove fats, waxes and chlorophyll from the CBD extract; filtering the CBD extract through a series of filter plates; removing carboxylic acid and CO2 from the CBD extract; removing impurities from the CBD extract by distillation; and crystallizing the purified CBD extract to produce pure CBD isolate crystals and chopping the pure CBD isolate crystals to produce crystals of between 200 and 600 microns in size. A further embodiment includes the steps of grinding the CBD isolate crystals and salt to produce micro-particles of between 1 and 40 microns and/or macro-particles of between 41 and 100 microns and releasing the particles into an air environment.

Abstract: The present invention concerns a stable aqueous composition comprising at least one human milk oligosaccharide for use in reducing time to reach full enteral feeding in preterm infants; wherein the composition is administered as soon as possible after birth between day 1 and 7 of life. Aqueous composition for use according to present invention is a milk fortifier or a supplement.

Abstract: This disclosure features methods to treat autoimmune diseases using compounds that activate the unfolded protein response (UPR) and/or compounds that disrupt the tricarboxylic acid (TCA) cycle in immune cells such as plasmacytoid dendritic cells. The disclosure also features method of reducing production of inflammatory cytokines or chemokines by immune cells.

Abstract: The present application relates to a novel conjugate group linkable to a compound (such as a therapeutic compound), for use in directing the compound to a target in the body. The conjugate group disclosed herein can enable an expression-inhibitory oligonucleotide (such as a RNAi reagent) to target liver cells to regulate gene expression. The conjugate group disclosed herein has a variety of applications when linked to expression-inhibitory oligonucleotides, comprising applications in therapy, diagnosis, target verification, and genome development. A composition comprising the conjugate group disclosed herein can mediate expression of target nucleic acid sequences in liver cells (such as hepatocytes) when linked to expression-inhibitory oligonucleotides, and can be used for treatment of diseases or disorders responding to the gene expression or activity of cells, tissues, or organisms.

Abstract: Provided herein are RNA-enriched compositions that can be used to treat age-related disorders. Also provided herein are methods for producing a such compositions.

Abstract: Provided herein are methods of administering ISIS 678354 for ameliorating Familial Chylomicronemia Syndrome (FCS), Familial Partial Lipodystrophy (FPL), Severe Hypertriglyceridemia (SHTG), reducing APOCIII RNA, or reducing APOCIII protein in a human subject in need thereof. In certain instances, methods are useful for ameliorating at least one symptom of FCS, FPL, or SHTG. Such symptoms of FCS include, but are not limited to, severe elevations in chylomicrons and extremely elevated TG levels (always reaching well above 1000 mg/dL and not infrequently rising as high as 10,000 mg/dL or more) with episodes of abdominal pain, physical fatigue, difficulty thinking, diarrhea, recurrent acute pancreatitis, eruptive cutaneous xanthomata, and hepatosplenomegaly.

Abstract: A method for treating an aneurysm in accordance with a particular embodiment of the present technology includes intravascularly delivering a mixture including a biopolymer (e.g., chitosan) and a chemical crosslinking agent (e.g., genipin) to an aneurysm. The method further includes mixing the biopolymer and the chemical crosslinking agent to initiate chemical crosslinking of the biopolymer. The mixture is delivered to the aneurysm via a lumen and an exit port of a catheter while the chemical crosslinking is ongoing. The mixture exits the catheter as a single cohesive strand that at least partially agglomerates to form a mass occupying at least 75% of a total internal volume of the aneurysm. During delivery of the mixture, the method includes expanding a tubular flow diverter to reinforce a neck of the aneurysm.

Abstract: A method for identifying and/or for obtaining active substances for the alleviation or treatment of ALS includes: a. providing a composition containing cells having the cell surface receptors syndecan-3 and/or syndecan-1, b. contacting the composition from step a) with SOD1 aggregates, c. contacting the composition from step a) with the test substance to be screened, it being possible for step b) and step c) to be performed simultaneously or for step c) to be performed before step b), and d. determining the uptake of the SOD1 aggregates into the cells, and a kit for carrying out the method, are provided. Medicaments comprising pentosan polysulfate sodium (PPS) or compounds from the group of heparins or heparin-like compounds, and methods of using the same, are also provided.

Abstract: Disclosed herein are compositions and methods of making and using such compositions. Polyhydric polymers may be converted to derivatives thereof by reaction with divinyl sulfone to provide vinyl sulfone substituted polymers, where the polymers may additionally be crosslinked, and the crosslinked and non-crosslinked derivatives may be used in biomedical and other applications.

Abstract: Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.

Abstract: Provided herein are methods and compositions for modulating a microorganism's response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a microbial infection comprising administering to a subject in need an effective amount of (i) bicarbonate and (ii) an antimicrobial agent. Also provided herein are methods of screening for antimicrobial compounds.

Abstract: This invention relates generally to an emollient topical composition of matter that contains molecular iodine with a reduced effective vapor pressure. In specific embodiments, the composition reduces the loss of molecular iodine to the atmosphere under storage conditions after application to mammalian tissue.

Abstract: The present invention provides antimicrobial feed supplement compositions comprising clay, and methods of treating microbial infections in an animal using the antimicrobial compositions.

Abstract: The present invention relates to compositions for mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided. In particular, the invention relates to a method of mineralizing a dental surface or subsurface comprising contacting the dental surface or subsurface with a compound that is capable of increasing or maintaining the pH of a solution and a mineralizing agent.

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein each of the first and second CARs is an activating CAR comprising an activating endodomain.

Abstract: Provided herein are gRNA comprising a targeting domain that targets CD7, which may be used, for example, to make modifications in cells. Also provided herein are methods of genetically engineered cell having a modification (e.g., insertion or deletion) in the CD7 gene and methods involving administering such genetically engineered cells to a subject, such as a subject having a hematopoietic malignancy.

Abstract: Provided is an anti-mesothelin chimeric antigen receptor that specifically binds to mesothelin. The anti-mesothelin chimeric antigen receptor according to an aspect exhibits a specific binding ability for mesothelin, and thus, may be useful for preventing or treating cancer in which mesothelin is overexpressed.

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a transmembrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.

Abstract: Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.

Abstract: Disclosures herein relate to methods of producing oral powdered compositions for fecal microbiota transplant and related methods of treatment. Procedures for producing the powdered composition may include filtering a fecal sample with a filter medium to generate a filtrate, separating particulate matter of the filtrate to obtain a first sediment and a first supernatant, repeatedly resuspending the first sediment and separating particulate matter of the resuspended first sediment to obtain a second sediment and a second supernatant, diluting the second supernatant and repeatedly separating particulate matter out of the second supernatant to obtain a third sediment and a third supernatant, resuspending the third sediment in a cryoprotectant to obtain a mixture, and freeze-drying the mixture to obtain a freeze-dried, powdered composition, wherein the powdered composition may be substantially tasteless, odorless, and colorless.

Abstract: Disclosures herein relate to a fecal microbiota transplant (FMT) composition for oral delivery, the FMT composition comprising an FMT including desired fecal microbes, wherein the FMT has an odor as evaluated with a confidence of 95% to be odorless for more than 50% of the population using a triangular test, wherein the FMT has a flavor as evaluated with a confidence of 80% to be flavorless for more than 50% of the population using the triangular test.

Abstract: The present invention addresses the problem of providing a therapeutic agent that is more efficacious for treating nerve disorders, said therapeutic agent comprising a culture supernatant of mesenchymal stem cells. The present invention provides a therapeutic agent for nerve disorders, said therapeutic agent comprising a culture supernatant of mesenchymal stem cells and/or cells capable of differentiating into mesenchymal stem cells and being to be used together with stimulation of patient's nerves, wherein the stimulation is preferentially provided to one or more sites selected from the group consisting of a site of nerve damage, an area surrounding a site of nerve damage, and a site compensating for the function of a site of nerve damage.

Abstract: The present application provides methods and processes for making and using a mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the mesenchymal stem cell secretome described herein.